Carol Aghajanian, MD
Chief, Gynecologic Medical Oncology Service
Memorial Sloan Kettering Cancer Center
Medicine
300 East 66th St.
New York,
NY
USA
10065
Papers:
136 - Scientific Plenary
A phase II evaluation of the potent, highly selective PARP inhibitor veliparib in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who carry a germline BRCA1 or BRCA2 m
137 - Scientific Plenary
Final analysis of overall survival in OCEANS, a randomized phase III trial of gemcitabine, carboplatin, and bevacizumab followed by bevacizumab until disease progression in patients with platinum-sensitive recurrent ovarian cancer
335 - Poster Session A
Combined modality adjuvant therapy for FIGO stage IIIC endometrial carcinomas
Questions & Panel Discussion
Late Breaking Abstract 1
A Randomized Phase III trial of pelvic radiation therapy (PXRT) versus vaginal cuff brachytherapy followed by paclitaxel/carboplatin chemotherapy (VCB/C) in patients with high risk (HR), early stage endometrial cancer (EC): A Gynecologic Oncology Group tr
Late Breaking Abstract 5
Risk of developing uterine corpus cancer (Ut Ca) following risk-reducing salpingo-oophorectomy (RRSO) in women with BRCA mutations